Condition
Hypertrophic Scarring
Total Trials
5
Recruiting
2
Active
2
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
5Total
Not Applicable (3)
P 2 (1)
P 4 (1)
Trial Status
Completed2
Recruiting2
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT07213544Phase 4Recruiting
Remimazolam vs Propofol in Laser Burn Cases
NCT07196358Not ApplicableCompletedPrimary
Topical Heparin for Prevention of Hypertrophic Scarring in Split-Thickness Skin Graft Donor Sites
NCT06104540Not ApplicableRecruiting
Comparison of the Effects of Liquid Vaseline and Olive Oil on Itching and Scarring in Scald Burns
NCT04756882Phase 2UnknownPrimary
Clinical Evaluation of the Efficacy OF Botulinum Toxin A for Improving Facial Scars
NCT01602458Not ApplicableCompletedPrimary
A Randomized Control Trial for Preventative Scar Management
Showing all 5 trials